Muscle Afferent Feedback Effects in Patients With Heart Failure

Status Completed

Clinical Trial Summary

The purpose of the study is to find out more about the mechanism by which neural feedback from the working muscle affects the development of central fatigue during exercise. Subjects with chronic heart failure (HF) and healthy subject counterparts will be tested to determine the mechanisms accounting for the premature fatigue characterizing HF patients during physical activity.

Clinical Trial Description

A substantial part in limiting exercise and/or physical activity in humans results from the development of peripheral and central fatigue during physical activity. Peripheral fatigue comprises biochemical changes within the metabolic milieu of the working muscle leading to an attenuated response to neural excitation, while central fatigue comprises a failure of the central nervous system to drive motoneurons.

Patients with HF have overactive group III/IV muscle afferents and an exaggerated development of central fatigue during physical activity that is not explained by their reduced physical conditioning or cardiac insufficiency caused by their failing heart. The exact mechanisms accounting for the exaggerated central fatigue in HF remains elusive, however, the development of central fatigue during exercise has recently been linked to signaling by group III/IV muscle afferents. This makes the heightened neural feedback in HF a likely candidate for these patients' increased susceptibility to central fatigue.

Lower pH, increased lactate and increased adenosine triphosphate has been shown to activate group III/IV afferents in a physiological manner and thus induce, in a rested and unfatigued muscle, the intramuscular milieu associated with moderate to heavy exercise. The objective of this study is to quantitate and compare the sensitivity of group III/IV afferents and associated effects on central fatigue in HF patients and healthy controls when skeletal muscle is subject to controlled lower pH, increased lactate and increased adenosine triphosphate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01919918
Study type	Interventional
Source	University of Utah
Contact
Status	Completed
Phase	Phase 1
Start date	September 2013
Completion date	January 3, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03597646` - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure	N/A
Terminated	`NCT04065997` - Apogee International
Withdrawn	`NCT03675113` - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure	N/A
Completed	`NCT02916160` - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study	Phase 4
Completed	`NCT03126656` - Effects of Testosterone on Myocardial Repolarization	Phase 4
Completed	`NCT02268500` - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)	Phase 4
Completed	`NCT02247245` - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.	N/A
Terminated	`NCT01906957` - Cognition and Exercise Training	N/A
Not yet recruiting	`NCT01669395` - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial	N/A
Completed	`NCT00984529` - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia	N/A
Recruiting	`NCT00863421` - Sleep Disordered Breathing in Patients With Chronic Heart Failure	N/A
Completed	`NCT02840565` - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453	Phase 1
Completed	`NCT02441218` - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study	Phase 3
Completed	`NCT00149409` - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure	Phase 2/Phase 3
Terminated	`NCT05532046` - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)	Phase 1
Recruiting	`NCT04984928` - Readmission Risk of Patients With Heart Failure.
Completed	`NCT02814097` - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction	Phase 2
Active, not recruiting	`NCT05560737` - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting	`NCT03286127` - Palliative Outcome Evaluation Muenster I
Not yet recruiting	`NCT06002321` - Right Ventricular Dysfunction in Chronic Heart Failure